Compared with parental cells, B-ALL cells resistant to CD19-targeted therapy, in the patients as well as in vitro, expressed less CD22, even though there was no CD22-targeted treatment to select for such suppression. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.